Global Nanostructured Drug Market Insights, Research, Forecast to 2025

Published On: Aug 2019

Format: PDF

Publisher: QY Research

Pages: 128

Report ID: 347633

The global Nanostructured Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nanostructured Drug market based on company, product type, end user and key regions.

This report studies the global market size of Nanostructured Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Nanostructured Drug in these regions.
This research report categorizes the global Nanostructured Drug market by top players/brands, region, type and end user. This report also studies the global Nanostructured Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma 
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy

Market size by Product
Liposomes
Polymeric Micelles
Solid lipid Nanoparticles
Microemulsion and Nanoemulsion
Nanosuspension
Market size by End User
Cancer and Tumors
Autoimmune Disorders

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Nanostructured Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Nanostructured Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Nanostructured Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Nanostructured Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Nanostructured Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nanostructured Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Nanostructured Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Nanostructured Drug Market Size Growth Rate by Product
1.4.2 Liposomes
1.4.3 Polymeric Micelles
1.4.4 Solid lipid Nanoparticles
1.4.5 Microemulsion and Nanoemulsion
1.4.6 Nanosuspension
1.5 Market by End User
1.5.1 Global Nanostructured Drug Market Size Growth Rate by End User
1.5.2 Cancer and Tumors
1.5.3 Autoimmune Disorders
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Nanostructured Drug Market Size
2.1.1 Global Nanostructured Drug Revenue 2014-2025
2.1.2 Global Nanostructured Drug Sales 2014-2025
2.2 Nanostructured Drug Growth Rate by Regions
2.2.1 Global Nanostructured Drug Sales by Regions
2.2.2 Global Nanostructured Drug Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Nanostructured Drug Sales by Manufacturers
3.1.1 Nanostructured Drug Sales by Manufacturers
3.1.2 Nanostructured Drug Sales Market Share by Manufacturers
3.1.3 Global Nanostructured Drug Market Concentration Ratio (CR5 and HHI)
3.2 Nanostructured Drug Revenue by Manufacturers
3.2.1 Nanostructured Drug Revenue by Manufacturers (2014-2019)
3.2.2 Nanostructured Drug Revenue Share by Manufacturers (2014-2019)
3.3 Nanostructured Drug Price by Manufacturers
3.4 Nanostructured Drug Manufacturing Base Distribution, Product Types
3.4.1 Nanostructured Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Nanostructured Drug Product Type
3.4.3 Date of International Manufacturers Enter into Nanostructured Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Nanostructured Drug Sales by Product
4.2 Global Nanostructured Drug Revenue by Product
4.3 Nanostructured Drug Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Nanostructured Drug Breakdown Data by End User

6 North America
6.1 North America Nanostructured Drug by Countries
6.1.1 North America Nanostructured Drug Sales by Countries
6.1.2 North America Nanostructured Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Nanostructured Drug by Product
6.3 North America Nanostructured Drug by End User

7 Europe
7.1 Europe Nanostructured Drug by Countries
7.1.1 Europe Nanostructured Drug Sales by Countries
7.1.2 Europe Nanostructured Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Nanostructured Drug by Product
7.3 Europe Nanostructured Drug by End User

8 Asia Pacific
8.1 Asia Pacific Nanostructured Drug by Countries
8.1.1 Asia Pacific Nanostructured Drug Sales by Countries
8.1.2 Asia Pacific Nanostructured Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Nanostructured Drug by Product
8.3 Asia Pacific Nanostructured Drug by End User

9 Central & South America
9.1 Central & South America Nanostructured Drug by Countries
9.1.1 Central & South America Nanostructured Drug Sales by Countries
9.1.2 Central & South America Nanostructured Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Nanostructured Drug by Product
9.3 Central & South America Nanostructured Drug by End User

10 Middle East and Africa
10.1 Middle East and Africa Nanostructured Drug by Countries
10.1.1 Middle East and Africa Nanostructured Drug Sales by Countries
10.1.2 Middle East and Africa Nanostructured Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Nanostructured Drug by Product
10.3 Middle East and Africa Nanostructured Drug by End User

11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Company Business Overview
11.1.3 Merck Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Merck Nanostructured Drug Products Offered
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Pfizer Nanostructured Drug Products Offered
11.2.5 Pfizer Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Company Business Overview
11.3.3 Novartis Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Novartis Nanostructured Drug Products Offered
11.3.5 Novartis Recent Development
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Company Business Overview
11.4.3 Abbott Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Abbott Nanostructured Drug Products Offered
11.4.5 Abbott Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 Company Business Overview
11.5.3 GlaxoSmithKline Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.5.4 GlaxoSmithKline Nanostructured Drug Products Offered
11.5.5 GlaxoSmithKline Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Company Business Overview
11.6.3 Roche Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Roche Nanostructured Drug Products Offered
11.6.5 Roche Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Company Business Overview
11.7.3 Sanofi Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Sanofi Nanostructured Drug Products Offered
11.7.5 Sanofi Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Company Business Overview
11.8.3 Eli Lilly Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Eli Lilly Nanostructured Drug Products Offered
11.8.5 Eli Lilly Recent Development
11.9 Astrazeneca
11.9.1 Astrazeneca Company Details
11.9.2 Company Business Overview
11.9.3 Astrazeneca Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Astrazeneca Nanostructured Drug Products Offered
11.9.5 Astrazeneca Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Company Business Overview
11.10.3 Johnson & Johnson Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Johnson & Johnson Nanostructured Drug Products Offered
11.10.5 Johnson & Johnson Recent Development
11.11 Celgene
11.12 Novavax
11.13 Stryker
11.14 Gilead Sciences
11.15 OSI Pharmaceuticals
11.16 Kadmon Pharmaceuticals
11.17 Samyang Biopharm
11.18 Mitsubishi Pharma 
11.19 Kaken Pharmaceutical
11.20 Selecta Biosciences
11.21 Par Pharmaceutical
11.22 Cerulean Pharma
11.23 Navidea Biopharmaceuticals
11.24 Lummy

12 Future Forecast
12.1 Nanostructured Drug Market Forecast by Regions
12.1.1 Global Nanostructured Drug Sales Forecast by Regions 2019-2025
12.1.2 Global Nanostructured Drug Revenue Forecast by Regions 2019-2025
12.2 Nanostructured Drug Market Forecast by Product
12.2.1 Global Nanostructured Drug Sales Forecast by Product 2019-2025
12.2.2 Global Nanostructured Drug Revenue Forecast by Product 2019-2025
12.3 Nanostructured Drug Market Forecast by End User
12.4 North America Nanostructured Drug Forecast
12.5 Europe Nanostructured Drug Forecast
12.6 Asia Pacific Nanostructured Drug Forecast
12.7 Central & South America Nanostructured Drug Forecast
12.8 Middle East and Africa Nanostructured Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Nanostructured Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer